Established in the year 1991 under the dynamic leadership of Mr. K Subba Rao, Chairman, VEF, the Institution has grown leaps and bounds. The first batch of students passed out of the college on 8th November 1995 which happens to be the red letter day when the premier Dental Council of India gave recognition to the Institution.
“Vignan Educational Foundation” which is a registered trust established in the Garden city of Bengaluru in the year 1991
 

ADMISSION – NOTICE (2013-2014)
FELLOWSHIP PROGRAMMES
(Recognized Certified Programme by RGUHS, Karnataka)

Readmore
“Vignan Educational Foundation” which is a registered trust established in the Garden city of Bengaluru in the year 1991 has today reached excellence in various fields of education in India and abroad.
Bangalore Institute of Dental Sciences and Hospital and Postgraduate Research Centre, Bengaluru
Vignan Institute of Nursing, Bengaluru
1. Oral Medicine and Radiology
2. Oral & Maxillofacial Surgery
3. Orthodontics & Dentofacial Orthopaedics
4. Periodontia
5. Prosthodontia
6. Conservative Dentistry and Endodontics
7. Oral Pathology and Microbiology.
8. Public Health Dentistry.
9. Preventing and Pediatric Dentistry
 

Says Scott Waldman.

The experts have identified a fresh degree of biological regulation and possibly an improved method to profile tumors, says Scott Waldman, M.D., Ph.D., professor and seat of pharmacology and experimental therapeutics at Jefferson Medical University of Thomas Jefferson University in Philadelphia, who co-wrote an editorial approximately the scholarly research appearing Might 2, 2007 in the journal JAMA, the Journal of the American Medical Association. The results are significant because they appear to represent a huge area of the machinery in the cell that regulates the processing of info from chromosome and gene to the proteins machinery which makes the cell operate, says Dr.It’s estimated that Diabetes will affect 400 million people globally by 2030 , with an expected 1 in 5 diabetics in India. The Diabetes pandemic can be alarming in developed countries, like the United States, which includes 18 million diabetics and a healthcare price burden of around $200 billion each year linked to the disease. By 2030, the amount of people coping with Diabetes in the U.S. Is likely to increase to 30 million. Commenting upon this main alliance, Kiran Mazumdar-Shaw, chairman and managing director of Biocon, said: ‘That is indeed a substantial inflection point inside our globalization path. Pfizer and Biocon gather a winning mix of marketing, research and production excellence which can create a formidable global footprint in Diabetes care.